Now Approved

Our immunotherapy has been approved for a new use in advanced bladder cancer.

Read More

Responding to COVID-19

We are taking actions to minimize the spread of the virus while ensuring that our medicines and services continue to reach those who rely on them.

Our Response

Cutting Edge Research

Building on our legacy of neurology, fertility and endocrinology, we are developing new oncology, immunology and immuno-oncology medicines.

Learn More About Our Research

Redirect

You have accessed https://www.emdserono.com, but for users from your part of the world, we originally designed the following web presence https://www.merckgroup.com.

Let's go

Site Exit Disclaimer

You are now leaving the website of EMD Serono, the biopharma business of Merck KGaA, Darmstadt, Germany. This link will either lead to a different website maintained by EMD Serono/its global business, or a different website/resource maintained by 3rd parties.

If you are visiting a 3rd party website, we have no control over the content and are not responsible for and make no representation as to the accuracy or any other aspect of such resource or the privacy practices of such 3rd party. Providing links to a 3rd party website does not constitute EMD Serono’s endorsement of such website or the information or products presented on such website. 

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement